NCT00162279已完成2 期
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis
Bristol-Myers Squibb35 个研究点 分布在 1 个国家目标入组 141 人开始时间: 2000年10月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 141
- 试验地点
- 35
- 主要终点
- Abatacept combined with etanercept will have greater clinical efficacy compared to subjects receiving etanercept alone
研究概览
简要总结
The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects who had completed the short term portion of IM101-101.
排除标准
- 未提供
结局指标
主要结局
Abatacept combined with etanercept will have greater clinical efficacy compared to subjects receiving etanercept alone
时间窗: at 6 months
次要结局
- ACR 50 and 70 will be evaluated(at 6 months)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
3 期
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic ArthritisPsoriatic ArthritisNCT02376790Amgen851
已完成
3 期
Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural ChangesSpondylitis, AnkylosingNCT01258738Pfizer225
终止
2 期
Use of Etanercept in the Treatment of Moderate to Severe Lichen PlanusLichen PlanusNCT00285779Stanford University27
已完成
2 期
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary FibrosisPulmonary FibrosisNCT00063869Wyeth is now a wholly owned subsidiary of Pfizer88
终止
2 期
Efficacy and Safety Study of Abatacept to Treat Lupus NephritisSystemic Lupus ErythematosusNCT00430677Bristol-Myers Squibb423